Evidence map›Paper›PMID 36978365›Full record

ArticleAntibiotics (Basel, Switzerland)2023

Gut Microbiota Composition Can Predict Colonization by Multidrug-Resistant Bacteria in SARS-CoV-2 Patients in Intensive Care Unit: A Pilot Study.

Jorge García-García, Patricia Diez-Echave, María Eugenia Yuste, Natalia Chueca, Federico García, Jose Cabeza-Barrera, Emilio Fernández-Varón, Julio Gálvez, Manuel Colmenero, Maria Elena Rodríguez-Cabezas and 2 more

Open access · goldFull text read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Jorge García-GarcíaDepartment of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, 18071 Granada, Spain.ORCID 0000-0003-0925-9441
Patricia Diez-EchaveDepartment of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, 18071 Granada, Spain.ORCID 0000-0003-4493-3091
María Eugenia YusteInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18012 Granada, Spain.
Natalia ChuecaInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18012 Granada, Spain.ORCID 0000-0002-3420-3290
Federico GarcíaInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18012 Granada, Spain.ORCID 0000-0001-7611-781X
Jose Cabeza-BarreraInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18012 Granada, Spain.ORCID 0000-0002-2161-930X
Emilio Fernández-VarónDepartment of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, 18071 Granada, Spain.ORCID 0000-0001-8253-6252
Julio GálvezDepartment of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, 18071 Granada, Spain.ORCID 0000-0001-6876-3782
Manuel ColmeneroInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18012 Granada, Spain.ORCID 0000-0001-5005-1154
Maria Elena Rodríguez-CabezasDepartment of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, 18071 Granada, Spain.ORCID 0000-0001-9085-8147
Alba Rodríguez-NogalesDepartment of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, 18071 Granada, Spain.ORCID 0000-0003-1927-0628
Rocío MorónInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18012 Granada, Spain.
Instituto de Investigación Biosanitaria de Granada · ESUniversidad de Granada · ES

Funding

Instituto de Salud Carlos III PI19/01058Instituto de Salud Carlos III PI20/01447Regional Government of Andalusia CTS164Regional Government of Andalusia CV20-77708
6 · The paper itself

Abstract

The SARS-CoV-2 infection has increased the number of patients entering Intensive Care Unit (ICU) facilities and antibiotic treatments. Concurrently, the multi-drug resistant bacteria (MDRB) colonization index has risen. Considering that most of these bacteria are derived from gut microbiota, the study of its composition is essential. Additionally, SARS-CoV-2 infection may promote gut dysbiosis, suggesting an effect on microbiota composition. This pilot study aims to determine bacteria biomarkers to predict MDRB colonization risk in SARS-CoV-2 patients in ICUs. Seventeen adult patients with an ICU stay >48 h and who tested positive for SARS-CoV-2 infection were enrolled in this study. Patients were assigned to two groups according to routine MDRB colonization surveillance: non-colonized and colonized. Stool samples were collected when entering ICUs, and microbiota composition was determined through Next Generation Sequencing techniques. Gut microbiota from colonized patients presented significantly lower bacterial diversity compared with non-colonized patients (

Indexed as

Intensive Care Unitmicrobiomemultidrug-resistant bacteriaSARS-CoV-2

Identifiers

PMID36978365
PMCPMC10044413
OpenAlexW4322760679

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read18
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.